Eiger BioPharmaceuticals (EIGR) Upgraded by Zacks Investment Research to Hold

Eiger BioPharmaceuticals stock has undergone multiple analysts rating changes in the recent past.  Eiger BioPharmaceuticals Upgraded by Zacks Investment Research on 10-11-21. In a note to investors, the firm issued a new rating of Hold. The analysts previously had rating of Sell.

Shares of Eiger BioPharmaceuticals traded up $0.10 on Monday, reaching $6.56. 115669 shares of the stock traded hands, compared to its average volume of 185296. Shares of Eiger BioPharmaceuticals were trading at $6.56 on Monday. The firm’s 50 day moving average is $7.59 and its 200 day moving average is $8.86.Eiger BioPharmaceuticals has a 12 month low of $6.40 and a 12 month high of $13.49. While on yearly highs and lows, Eiger BioPharmaceuticals’s today has traded high as $6.70 and has touched $6.40 on the downward trend. See More Analyst Rating at: RATING

Eiger BioPharmaceuticals Earnings and What to expect: 

Eiger BioPharmaceuticals last posted its earnings results on August 5th, 2021. The biotechnology company reported ($0.57) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.54) by $0.03. The business had revenue of $2.10 million for the quarter, compared to the consensus estimate of $1.62 million. Eiger BioPharmaceuticals has generated ($2.31) earnings per share over the last year (($0.82) diluted earnings per share). Earnings for Eiger BioPharmaceuticals are expected to grow in the coming year, from ($2.84) to ($1.84) per share. Eiger BioPharmaceuticals has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Thursday, November 4th, 2021 based off prior year’s report dates.

Earnings for Eiger BioPharmaceuticals are expected to grow in the coming year, from ($2.84) to ($1.84) per share. The P/E ratio of Eiger BioPharmaceuticals is -8.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Eiger BioPharmaceuticals is -8.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Eiger BioPharmaceuticals has a P/B Ratio of 2.25. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Eiger BioPharmaceuticals (EIGR) Moving Average Technical Analysis

5 day Moving Average is $6.47 And 5 day price change is $0.04 (0.61%)  with average volume for 5 day average is 165,900. While technical analysis for average 20 days shows significant difference, 20 day moving average is  $6.87 and 20 day price change is -$1.01 (-13.34%) and average 20 day moving volume is 196,960. 50 day moving average is $7.59  and 50 day price change is -$1.40 ( -17.59%)  and with average volume for 50 days is : 182,122. 200 day moving average is $8.86  and 200 day price change is -$3.54 (-35.05%)  and with average volume for 200 days is : 219,725.

Other owners latest trading in Eiger BioPharmaceuticals :

  • On 8/23/2021 shares held by Morgan Stanley were 115,488 which equates to market value of $0.99M and appx 0.00% owners of Eiger BioPharmaceuticals
  • On 8/17/2021 shares held by Wells Fargo & Company MN were 10,274 which equates to market value of $87K and appx 0.00% owners of Eiger BioPharmaceuticals
  • On 8/17/2021 shares held by Weiss Multi Strategy Advisers LLC were 207,000 which equates to market value of $1.76M and appx 0.00% owners of Eiger BioPharmaceuticals
  • In total Institutional ownership equates to Institutional Ownership Percentage: 68.68% for Eiger BioPharmaceuticals

See More Analyst Rating at: RATING